MapLight Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-60.2M | $-60.7M | $-79.5M | $-29.4M | $-29.8M | $-22.3M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $147.0K | $162.0K | $176.0K | $100.0K | $136.0K | $166.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $8.6M | $9.6M | $35.5M | $125.0K | $148.0K | $212.0K |
| Net Cash from Operating Activities | $-44.9M | $-51.2M | $-46.8M | $-31.8M | $-34.0M | $-25.6M |
| Investing Activities | ||||||
| Capital Expenditures | $22.0K | $24.0K | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $60.7M | $67.0M | $-242.6M | $-135.6M | $17.4M | $37.5M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $92.0K | $-6.9M | $272.0M | $198.1M | $-156.0K | $-47.0K |
| Net Change in Cash | — | — | — | — | — | — |
| Free Cash Flow | $-44.9M | $-51.2M | — | — | — | — |